243 related articles for article (PubMed ID: 38658543)
41. A model for transmission of the H3K27me3 epigenetic mark.
Hansen KH; Bracken AP; Pasini D; Dietrich N; Gehani SS; Monrad A; Rappsilber J; Lerdrup M; Helin K
Nat Cell Biol; 2008 Nov; 10(11):1291-300. PubMed ID: 18931660
[TBL] [Abstract][Full Text] [Related]
42. Histone H3 tail binds a unique sensing pocket in EZH2 to activate the PRC2 methyltransferase.
Jani KS; Jain SU; Ge EJ; Diehl KL; Lundgren SM; Müller MM; Lewis PW; Muir TW
Proc Natl Acad Sci U S A; 2019 Apr; 116(17):8295-8300. PubMed ID: 30967505
[TBL] [Abstract][Full Text] [Related]
43. Full methylation of H3K27 by PRC2 is dispensable for initial embryoid body formation but required to maintain differentiated cell identity.
Miller SA; Damle M; Kim J; Kingston RE
Development; 2021 Apr; 148(7):. PubMed ID: 33688077
[TBL] [Abstract][Full Text] [Related]
44. BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
Gorodetska I; Lukiyanchuk V; Peitzsch C; Kozeretska I; Dubrovska A
Int J Cancer; 2019 Dec; 145(11):2974-2985. PubMed ID: 30968962
[TBL] [Abstract][Full Text] [Related]
45. EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma.
Yan J; Li B; Lin B; Lee PT; Chung TH; Tan J; Bi C; Lee XT; Selvarajan V; Ng SB; Yang H; Yu Q; Chng WJ
Blood; 2016 Aug; 128(7):948-58. PubMed ID: 27297789
[TBL] [Abstract][Full Text] [Related]
46. Flow-dependent epigenetic regulation of IGFBP5 expression by H3K27me3 contributes to endothelial anti-inflammatory effects.
Xu S; Xu Y; Yin M; Zhang S; Liu P; Koroleva M; Si S; Little PJ; Pelisek J; Jin ZG
Theranostics; 2018; 8(11):3007-3021. PubMed ID: 29896299
[No Abstract] [Full Text] [Related]
47. Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.
Agarwal P; Alzrigat M; Párraga AA; Enroth S; Singh U; Ungerstedt J; Österborg A; Brown PJ; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2016 Feb; 7(6):6809-23. PubMed ID: 26755663
[TBL] [Abstract][Full Text] [Related]
48. An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.
Souroullas GP; Jeck WR; Parker JS; Simon JM; Liu JY; Paulk J; Xiong J; Clark KS; Fedoriw Y; Qi J; Burd CE; Bradner JE; Sharpless NE
Nat Med; 2016 Jun; 22(6):632-40. PubMed ID: 27135738
[TBL] [Abstract][Full Text] [Related]
49. PRC2-Mediated Epigenetic Suppression of Type I IFN-STAT2 Signaling Impairs Antitumor Immunity in Luminal Breast Cancer.
Hong J; Lee JH; Zhang Z; Wu Y; Yang M; Liao Y; de la Rosa R; Scheirer J; Pechacek D; Zhang N; Xu Z; Curiel T; Tan X; Huang TH; Xu K
Cancer Res; 2022 Dec; 82(24):4624-4640. PubMed ID: 36222718
[TBL] [Abstract][Full Text] [Related]
50. Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis.
Zeng Y; Qiu R; Yang Y; Gao T; Zheng Y; Huang W; Gao J; Zhang K; Liu R; Wang S; Hou Y; Yu W; Leng S; Feng D; Liu W; Zhang X; Wang Y
Cell Rep; 2019 Nov; 29(6):1482-1498.e4. PubMed ID: 31693890
[TBL] [Abstract][Full Text] [Related]
51. EZH2 alterations in follicular lymphoma: biological and clinical correlations.
Huet S; Xerri L; Tesson B; Mareschal S; Taix S; Mescam-Mancini L; Sohier E; Carrère M; Lazarovici J; Casasnovas O; Tonon L; Boyault S; Hayette S; Haioun C; Fabiani B; Viari A; Jardin F; Salles G
Blood Cancer J; 2017 Apr; 7(4):e555. PubMed ID: 28430172
[TBL] [Abstract][Full Text] [Related]
52. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.
Qi W; Chan H; Teng L; Li L; Chuai S; Zhang R; Zeng J; Li M; Fan H; Lin Y; Gu J; Ardayfio O; Zhang JH; Yan X; Fang J; Mi Y; Zhang M; Zhou T; Feng G; Chen Z; Li G; Yang T; Zhao K; Liu X; Yu Z; Lu CX; Atadja P; Li E
Proc Natl Acad Sci U S A; 2012 Dec; 109(52):21360-5. PubMed ID: 23236167
[TBL] [Abstract][Full Text] [Related]
53. Molecular Mechanisms Directing PRC2 Recruitment and H3K27 Methylation.
Laugesen A; Højfeldt JW; Helin K
Mol Cell; 2019 Apr; 74(1):8-18. PubMed ID: 30951652
[TBL] [Abstract][Full Text] [Related]
54. Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation.
Zhou Z; Gao J; Popovic R; Wolniak K; Parimi V; Winter JN; Licht JD; Chen YH
Leuk Lymphoma; 2015; 56(10):2895-901. PubMed ID: 25651430
[TBL] [Abstract][Full Text] [Related]
55. Convergent evolution of chromatin modification by structurally distinct enzymes: comparative enzymology of histone H3 Lys²⁷ methylation by human polycomb repressive complex 2 and vSET.
Swalm BM; Hallenbeck KK; Majer CR; Jin L; Scott MP; Moyer MP; Copeland RA; Wigle TJ
Biochem J; 2013 Jul; 453(2):241-7. PubMed ID: 23679895
[TBL] [Abstract][Full Text] [Related]
56. Epigenetic regulation of enhancer of zeste homolog 2 (EZH2) -Yin Yang 1 (YY1) axis in cancer.
Chandnani N; Gupta I; Thakkar V; Sarkar K
Pathol Res Pract; 2023 Nov; 251():154885. PubMed ID: 37862922
[TBL] [Abstract][Full Text] [Related]
57. Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas.
Yamagishi M; Hori M; Fujikawa D; Ohsugi T; Honma D; Adachi N; Katano H; Hishima T; Kobayashi S; Nakano K; Nakashima M; Iwanaga M; Utsunomiya A; Tanaka Y; Okada S; Tsukasaki K; Tobinai K; Araki K; Watanabe T; Uchimaru K
Cell Rep; 2019 Nov; 29(8):2321-2337.e7. PubMed ID: 31747604
[TBL] [Abstract][Full Text] [Related]
58. Histone H3.3 G34 mutations promote aberrant PRC2 activity and drive tumor progression.
Jain SU; Khazaei S; Marchione DM; Lundgren SM; Wang X; Weinberg DN; Deshmukh S; Juretic N; Lu C; Allis CD; Garcia BA; Jabado N; Lewis PW
Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27354-27364. PubMed ID: 33067396
[TBL] [Abstract][Full Text] [Related]
59. Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function.
Wan L; Xu K; Wei Y; Zhang J; Han T; Fry C; Zhang Z; Wang YV; Huang L; Yuan M; Xia W; Chang WC; Huang WC; Liu CL; Chang YC; Liu J; Wu Y; Jin VX; Dai X; Guo J; Liu J; Jiang S; Li J; Asara JM; Brown M; Hung MC; Wei W
Mol Cell; 2018 Jan; 69(2):279-291.e5. PubMed ID: 29351847
[TBL] [Abstract][Full Text] [Related]
60. Mechanisms of action and resistance in histone methylation-targeted therapy.
Yamagishi M; Kuze Y; Kobayashi S; Nakashima M; Morishima S; Kawamata T; Makiyama J; Suzuki K; Seki M; Abe K; Imamura K; Watanabe E; Tsuchiya K; Yasumatsu I; Takayama G; Hizukuri Y; Ito K; Taira Y; Nannya Y; Tojo A; Watanabe T; Tsutsumi S; Suzuki Y; Uchimaru K
Nature; 2024 Mar; 627(8002):221-228. PubMed ID: 38383791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]